ClinicalTrials.gg
Status unknownNCT02857959Updated Nov 16, 2018

One Dose Versus Three Weekly Doses of Benzathine Penicillin G for Patients With Early Syphilis

A Phase 4 interventional study of Benzathine Penicillin G in Syphilis, sponsored by Jun Li. Status unknown at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Jun Li · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to observe the serological response to 1 or 3 weekly doses of benzathine penicillin G in patients with early syphilis.

02

Conditions studied

  • Syphilis

Browse trials for

03

In context

Syphilis

126 studies on the registry are indexed under Syphilis; 33 are open to participants now.

This study's planned enrollment of 150 is below the median of 354 across 85 interventional studies indexed under Syphilis.

Browse Syphilis studies →

Lead sponsor

Jun Li is the lead sponsor of 10 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Persons with confirmed early symptomatic syphilis (primary or secondary) or high-titer latent syphilis
  2. A rapid plasma reagin (RPR) test was positive, with a titer were 1:4 or higher. In addition, Treponema pallidum particle agglutination assay and/or fluorescent treponemal antibody absorption test were reactive.

Exclusion criteria

Exclusion Criteria:

1.Patients who were pregnancy, known allergy to penicillin, use of antibiotics active against syphilis during the preceding six months for symptomatic cases or during the preceding two years for asymptomatic cases, and concurrent illnesses requiring treatment with antibiotics effective against syphilis. 2. if RPR titers were found to be 1:4 or less or the T. pallidum particle agglutination test was nonreactive, participants were retrospectively excluded from the trial unless primary syphilis was confirmed by the finding of T. pallidum in ulcer exudates on direct immunofluorescence

-

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    single dose benzathine penicillin G.

    single dose benzathine penicillin G.

    Drug: Benzathine Penicillin G

  • Active comparator
    three doses of benzathine penicillin G.

    three doses of benzathine penicillin G.

    Drug: Benzathine Penicillin G

Interventions

06

What researchers measure

Primary outcomes

  1. Rapid plasma reagin titers

    Time frame: up to 9 months after treatment

07

Study locations

1 of 1 sites recruiting
  • Department of Dermatology and Venereology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Beijing, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Jun 2020 and a completion of Aug 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2016
First posted
Aug 5, 2016
Start
Aug 2016
Primary completionEst.
Jun 2020
CompletionEst.
Aug 2020
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02857959
Lead sponsor
Jun Li
Responsible party
Jun Li (M.D., Peking Union Medical College Hospital) — Sponsor-investigator
First posted
Aug 5, 2016
Start date
Aug 2016
Primary completion
Jun 2020 (estimated)
Completion
Aug 2020 (estimated)
Last update
Nov 16, 2018

Study contacts

Jun Li, M.D.
Contact
lijun35@hotmail.com
86-010-69151504
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Penicillin G Benzathine

Start the discussion